Zobrazeno 1 - 10
of 2 488
pro vyhledávání: '"Nucleoside Reverse Transcriptase Inhibitor"'
Autor:
Jiafeng Zhang, Baochang Sun, Zihang Sheng, Xiaobei Ding, Qin Fan, Gang Huang, Zhihong Guo, Ping Zhong, Lingjie Liao, Hui Xing, Yan Xia, Chengliang Chai, Jianmin Jiang
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 900 (2024)
HIV drug resistance compromises the ability of anti-retroviral therapy (ART) to suppress viral replication, resulting in treatment failure. This study investigates the prevalence of pre-treatment drug resistance (PDR) in newly diagnosed individuals i
Externí odkaz:
https://doaj.org/article/d214be709b2d4367b46ba651c7d7c768
Publikováno v:
Infection and Drug Resistance, Vol Volume 16, Pp 4697-4706 (2023)
Shiyun Lv,1,* Lijun Sun,1,* Tongzeng Li,1,* Ruojing Bai,1 Man Dai,2,3 Ran Wang,1 Yuanyi Zhai,1 Wei Hua,1 Aixin Li,1 Ruolei Xin,2 Lili Dai1 1Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Instit
Externí odkaz:
https://doaj.org/article/35a6fce9df8648bcb089971e7eda5ef1
Autor:
Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Szu-Min Hsieh, Wang-Hui Sheng, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 56, Iss 5, Pp 988-995 (2023)
Background: Antiretroviral regimens containing a second-generation integrase strand-transfer inhibitor (INSTI) plus 2 nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) are the recommended therapy for people with HIV (PWH) who are antiretroviral-
Externí odkaz:
https://doaj.org/article/bd31ef3096004ae38af55854f8dc6ebe
Autor:
Wilhelm A. J. W. Vos, Nadira Vadaq, Vasiliki Matzaraki, Twan Otten, Albert L. Groenendijk, Marc J. T. Blaauw, Louise E. van Eekeren, Kees Brinkman, Quirijn de Mast, Niels P. Riksen, Anton F. H. Stalenhoef, Jan van Lunzen, Andre J. A. M. van der Ven, Willem L. Blok, Janneke E. Stalenhoef
Publikováno v:
Viruses, Vol 16, Iss 4, p 582 (2024)
In people living with HIV (PLHIV), integrase strand transfer inhibitors (INSTIs) are part of the first-line combination antiretroviral therapy (cART), while non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are alternatives. Disti
Externí odkaz:
https://doaj.org/article/f709bcd454a146f98691dffd7cf32341
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ashwini Yadav, Srikanth Prasad Tripathy, Tej Pal Singh, Srikanta Jena, Shripad A Patil, Keshar Kunja Mohanty
Publikováno v:
Journal of Krishna Institute of Medical Sciences University, Vol 12, Iss 1, Pp 17-23 (2023)
Background: The study analyses several first line and second line drugs, CD4 counts and viral load in patients experiencing treatment failure over a period of 1 to 6 years of first line Antiretroviral Therapy (ART). The study emphasizes the implement
Externí odkaz:
https://doaj.org/article/777478c349fa4ff3bb0a4ac4d2310600
Autor:
Mao-Song Tsai, Hsin-Yun Sun, Cheng-Pin Chen, Chen-Hsiang Lee, Chun-Yuan Lee, Chun-Eng Liu, Hung-Jen Tang, Tung-Che Hung, Chia-Wen Li, Yuan-Ti Lee, Bo-Huang Liou, Chia-Jui Yang, Chien-Ching Hung
Publikováno v:
International Journal of Infectious Diseases, Vol 126, Iss , Pp 39-47 (2023)
Objectives: Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV (PLWH) having achieved viral suppression after previous virologic failu
Externí odkaz:
https://doaj.org/article/74974abe7a07487f88a22c95815bc8ae
Autor:
Tiffany W. Chow, Mark Raupp, Matthew W. Reynolds, Siying Li, Gwendolyn E. Kaeser, Jerold Chun
Publikováno v:
Pharmaceuticals, Vol 17, Iss 4, p 408 (2024)
Brain somatic gene recombination (SGR) and the endogenous reverse transcriptases (RTs) that produce it have been implicated in the etiology of Alzheimer’s disease (AD), suggesting RT inhibitors as novel prophylactics or therapeutics. This retrospec
Externí odkaz:
https://doaj.org/article/df24aeded91845498e1dad45efb64b90
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk
Publikováno v:
HIV Research & Clinical Practice, Vol 23, Iss 1, Pp 9-14 (2021)
Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofov
Externí odkaz:
https://doaj.org/article/5ba59213feaa4f1abb8a36a2726d56ec